Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Randomized, Placebo-controlled Trial to Evaluate the Safety and Effect on Post-HIV Acquisition Viremia of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Transgender Women, Who Have Sex With Men.

Next Previous
Trial Profile

Phase 2, Randomized, Placebo-controlled Trial to Evaluate the Safety and Effect on Post-HIV Acquisition Viremia of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Transgender Women, Who Have Sex With Men.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VRC-HIVADV014-00-VP (Primary) ; VRC-HIVDNA016-00-VP (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 25 Apr 2013 Interim results published National Institute of Allergy and Infectious Diseases (NIAID) media release.
    • 25 Apr 2013 Status changed from recruiting to discontinued, according to National Institute of Allergy and Infectious Diseases (NIAID) media release.
    • 17 Sep 2012 Planned number of patients changed from 2200 to 2500.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top